ESMO 2023 | Enhancing immunotherapy response prediction in NSCLC

Immunotherapy has greatly impacted outcomes for patients with metastatic non-small cell lung cancer (NSCLC) outcomes, but predicting patient responses remains a challenge. Current biomarkers like PD-L1 and tumor mutational burden don’t always accurately predict response. Crispin Hiley, PhD, UCL Cancer Institute, London, UK, suggests that incorporating measures of clonality and heterogeneity into biomarker assessments could improve response prediction and identify patients suitable for combination immunotherapy studies. This approach may aid in selecting patients for novel therapies and experimental cellular treatments, potentially making it more effective to target clonal mutations over subclonal ones. The ongoing translational and biomarker research aims to enhance the management of metastatic non-small cell lung cancer and ultimately improve patient outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.